Vulva Cancer Histopathology Reporting Proforma

Size: px
Start display at page:

Download "Vulva Cancer Histopathology Reporting Proforma"

Transcription

1 Vulva Cancer Histopathology Reporting Proforma Mandatory questions (i.e. protocol standards) are in bold (e.g. S1.01). S1.01 Identification Family name Given name(s) Ethnicity Unknown AboriginalTorres Strait Islander ethnicity: Date of birth DD MM YYYY Date of request Mandatory questions (i.e. protocol standards) are in bold (e.g. S1.01). Requesting doctor - name and contact details DD MM YYYY Patient identifiers e.g. MRN, IHI or NHI (please indicate which) S1.03 Accession number Clinical diagnosis New primary, recurrence, precancer (VIN) or other previous cancer New primary cancer Details Precancer (VIN) Local recurrence (vulva) Regional recurrence (groin) Distant metastasis previous cancer diagnosis Lymph nodes None received OR Select all that apply: Right inguinal Left inguinal Right femerol Left femerol Accompanying specimens Right pelvic Left pelvic Right sentinel Left Sentinel Specimen site Method of treatment Number of tumours Surgical orientation markers Operative specimen Local resection Total radical vulvectomy Part of vulva, radically resected Describe below Type: Not stated Right Left Anterior Posterior S1.04 Principal clinician G1.01 clinical information Version 1.0 Proforma: Vulva Cancer Structured Reporting Protocol 1st Edition Page 1 of 9

2 Macroscopic findings features (shape, colour, demarcation): S2.01 Specimen orientation markers S2.05 Tumour dimensions G2.01 Surface anatomical structures (eg clitoris, urethralvaginal orifice etc) Type of surface: Hair bearing skin Hairless skinmucosa Both hair bearing and hairless skinmucosa Cannot determine S2.02 Specimen measurements length x width x thickness TUMOUR 3 S2.04 Macro. appearance of tumour Type of growth: Fungating Ulcerative features (shape, colour, demarcation): length x width x thickness S2.03 Number of macroscopically visible tumour(s) S2.05 Tumour dimensions length x width x thickness TUMOUR 1 S2.04 Macro. appearance of tumour Type of growth: Fungating Ulcerative S2.06 Margins Not assessable peripheral margin features (shape, colour, demarcation): Site(s) of involved margins S2.05 Tumour dimensions length x width x thickness S2.07 Adjacent skin abnormality No Yes Describe (eg. white, thickened) TUMOUR 2 S2.04 Macro. appearance of tumour Type of growth: Fungating Ulcerative S2.08 Macroscopic depth of invasion OR Not assessable Version 1.0 Proforma: Vulva Cancer Structured Reporting Protocol 1st Edition Page 2 of 9

3 S2.09 LYMPH NODES RIGHT INGUINAL LN RIGHT FEMORAL LN to LEFT INGUINAL LN to LEFT FEMORAL LN to to Version 1.0 Proforma: Vulva Cancer Structured Reporting Protocol 1st Edition Page 3 of 9

4 LEFT FEMORAL LN (cont.) LEFT PELVIC LN (cont.) RIGHT PELVIC LN RIGHT SENTINEL INGUINOFEMORAL LN to LEFT PELVIC LN to LEFT SENTINEL INGUINOFEMORAL LN to to Version 1.0 Proforma: Vulva Cancer Structured Reporting Protocol 1st Edition Page 4 of 9

5 LEFT SENT. INGUINOFEMORAL LN (Cont.) Microscopic findings S3.01 Number of primary tumours G3.01 Microscopic description S2.10 Block code Repeat the following set of information for each primary tumour identified in S3.01. TUMOUR 1 S3.02 Tumour type (of primary tumour) Squamous cell carcinoma S3.03 Depth of invasion G3.02 Superficial reference point for depth of invasion measurement From point of origin From most superficial epithelial-stromal interface (exophytic tumours only) From top of adjacent dermal papilla (for ulcerated tumours and where the point of origin is not known) S3.04 Size of microscopic tumour(s) (for each microscopic tumour identified that has not been identified previously in the macroscopic) S3.05 Lymphvascular space invasion S3.06 Perineural invasion Version 1.0 Proforma: Vulva Cancer Structured Reporting Protocol 1st Edition Page 5 of 9

6 S3.07 Margin status (invasive tumour) peripheral margin List involved margin(s) medial (vaginal) urethral anal clitoral other TUMOUR 2 (cont.) S3.07 Margin status (invasive tumour) peripheral margin List involved margin(s) medial (vaginal) urethral anal clitoral other TUMOUR 2 S3.02 Tumour type (of primary tumour) Squamous cell carcinoma TUMOUR 3 S3.02 Tumour type (of primary tumour) Squamous cell carcinoma S3.03 Depth of invasion G3.02 Superficial reference point for depth of invasion measurement From point of origin From most superficial epithelial-stromal interface (exophytic tumours only) From top of adjacent dermal papilla (for ulcerated tumours and where the point of origin is not known) S3.04 Size of microscopic tumour(s) (Complete for each microscopic tumour identified that has not been identified previously in the macroscopic) S3.03 Depth of invasion G3.02 Superficial reference point for depth of invasion measurement From point of origin From most superficial epithelial-stromal interface (exophytic tumours only) From top of adjacent dermal papilla (for ulcerated tumours and where the point of origin is not known) S3.04 Size of microscopic tumour(s) (Complete for each microscopic tumour identified that has not been identified previously in the macroscopic) S3.05 Lymphvascular space invasion S3.05 Lymphvascular space invasion S3.06 Perineural invasion S3.06 Perineural invasion Version 1.0 Proforma: Vulva Cancer Structured Reporting Protocol 1st Edition Page 6 of 9

7 TUMOUR 3 (cont.) S3.07 Margin status (invasive tumour) S3.08 Intraepithelial Neoplasia eg VIN, EMPD VIN-Differentiated VIN-Warty-basaloid (usual, HPV-assoc d) S3.09 Margin status (VINEMPD) Uncertain peripheral margin Type medial (vaginal) urethral anal clitoral other List involved margin(s) medial (vaginal) urethral anal clitoral other EMPD List involved margin(s) Node 2 Node 3 Node 4 LEFT INGUINAL LN Node 2 Node 3 Node 4 RIGHT FEMORAL LN LYMPH NODES RIGHT INGUINAL LN Node 2 Node 3 Node 4 Version 1.0 Proforma: Vulva Cancer Structured Reporting Protocol 1st Edition Page 7 of 9

8 LEFT FEMORAL LN Node 2 Node 3 Node 4 LEFT PELVIC LN (cont.) RIGHT SENTINEL INGUINOFEMORAL LN Node 2 RIGHT PELVIC LN Node 2 Node 3 Node 4 Node 3 Node 4 LEFT SENTINEL INGUINOFEMORAL LN LEFT PELVIC LN Node 2 Node 3 Node 4 G3.03 OTHER DIAGNOSES Histopathological features of lesions other than cancers Node 2 Node 3 Node 4 Lichen sclerosus Version 1.0 Proforma: Vulva Cancer Structured Reporting Protocol 1st Edition Page 8 of 9

9 G3.04 relevant microscopic coent Synthesis and overview G5.01 Diagnostic suary Include: operative procedure; tumour type; tumour size; depth of invasion; lymphvascular space invasion; status of margins; lymph node status Ancillary test findings S4.01 IMMUNOHISTOCHEMICAL STAINS SENTINEL NODES Positive Abs Negative Abs Equivocal Abs G5.02 Overarching coent Interpretive coent G4.01 ancillary tests Not performed Performed Type of test 1 (eg FISH, cytogenetics) Result Interpretive coent Type of test 2 (eg FISH, cytogenetics) Result Interpretive coent Type of test 3 (eg FISH, cytogenetics) Result Interpretive coent Worksheet prepared by: On: DD MM YYYY Version 1.0 Proforma: Vulva Cancer Structured Reporting Protocol 1st Edition Page 9 of 9

Tumours of the Oesophagus & Gastro-Oesophageal Junction Histopathology Reporting Proforma

Tumours of the Oesophagus & Gastro-Oesophageal Junction Histopathology Reporting Proforma Tumours of the Oesophagus & Gastro-Oesophageal Junction Histopathology Reporting Proforma Mandatory questions (i.e. protocol standards) are in bold (e.g. S1.01). S1.01 Identification Family name Given

More information

Gastric Cancer Histopathology Reporting Proforma

Gastric Cancer Histopathology Reporting Proforma Gastric Cancer Histopathology Reporting Proforma Mandatory questions (i.e. protocol standards) are in bold (e.g. S1.01). S1.01 Identification Family name Given name(s) Date of birth Sex Male Female Intersex/indeterminate

More information

Carcinoma of the Urinary Bladder Histopathology

Carcinoma of the Urinary Bladder Histopathology Carcinoma of the Urinary Bladder Histopathology Reporting Proforma (Radical & Partial Cystectomy, Cystoprostatectomy) Includes the International Collaboration on Cancer reporting dataset denoted by * Family

More information

Primary Cutaneous Melanoma Pathology Reporting Proforma DD MM YYYY. *Tumour site. *Specimen laterality. *Specimen type

Primary Cutaneous Melanoma Pathology Reporting Proforma DD MM YYYY. *Tumour site. *Specimen laterality. *Specimen type Primary Cutaneous Melanoma Pathology Reporting Proforma Includes the International Collaboration on Cancer reporting dataset denoted by * Family name Given name(s) Date of birth DD MM YYYY Sex Male Female

More information

Polypectomy and Local Resections of the Colorectum Structured Pathology Reporting Proforma

Polypectomy and Local Resections of the Colorectum Structured Pathology Reporting Proforma Polypectomy and Local Resections of the Colorectum Structured Pathology Reporting Proforma Mandatory questions (i.e. protocol standards) are in bold (e.g. S1.03). Family name Given name(s) Date of birth

More information

Carcinoma of the Renal Pelvis and Ureter Histopathology

Carcinoma of the Renal Pelvis and Ureter Histopathology Carcinoma of the Renal Pelvis and Ureter Histopathology Reporting Proforma (NEPHROURETERECTOMY AND URETERECTOMY) Includes the International Collaboration on Cancer reporting dataset denoted by * Family

More information

Colorectal Cancer Structured Pathology Reporting Proforma DD MM YYYY

Colorectal Cancer Structured Pathology Reporting Proforma DD MM YYYY Colorectal Cancer Structured Pathology Reporting Proforma Mandatory questions (i.e. protocol standards) are in bold (e.g. S1.03). Family name Given name(s) Date of birth DD MM YYYY S1.02 Clinical details

More information

S1.04 Principal clinician. G1.01 Comments. G2.01 *Specimen dimensions (prostate) S2.02 *Seminal vesicles

S1.04 Principal clinician. G1.01 Comments. G2.01 *Specimen dimensions (prostate) S2.02 *Seminal vesicles Prostate Cancer Histopathology Reporting Proforma (Radical Prostatectomy) Includes the International Collaboration on Cancer reporting dataset denoted by * Family name Given name(s) Date of birth Sex Male

More information

VULVAR CARCINOMA. Page 1 of 5

VULVAR CARCINOMA. Page 1 of 5 VULVAR CARCINOMA EXAMPLE OF A VULVAR CARCINOMA USING PROPOSED TEMPLATE Case: Invasive squamous cell carcinoma arising in D-VIN Tumor in left labia major Left partial vaginectomy and sentinel lymph node

More information

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER VULVAR

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER VULVAR PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER VULVAR Last Revision Date July 2015 1 Site Group: Gynecologic Cancer Vulvar Author: Dr. Stephane Laframboise 1. INTRODUCTION

More information

S1.04 PRINCIPAL CLINICIAN G1.01 COMMENTS S2.01 SPECIMEN LABELLED AS G2.01 *SPECIMEN DIMENSIONS (PROSTATE) S2.03 *SEMINAL VESICLES

S1.04 PRINCIPAL CLINICIAN G1.01 COMMENTS S2.01 SPECIMEN LABELLED AS G2.01 *SPECIMEN DIMENSIONS (PROSTATE) S2.03 *SEMINAL VESICLES Prostate Cancer Histopathology Reporting Proforma (Radical Prostatectomy) Includes the International Collaboration on Cancer reporting dataset denoted by * Family name Given name(s) Date of birth Indigenous

More information

FNA Thyroid Cytology Structured Reporting Proforma

FNA Thyroid Cytology Structured Reporting Proforma FNA Thyroid Cytology Structured Reporting Proforma Mandatory questions (i.e. protocol standards) are in bold (e.g. S1.03). Family name Given name(s) Date of birth S1.02 Clinical details Male Female Intersex/indeterminate

More information

SCAN Gynaecological Group. Clinical Management Protocols vulval cancer

SCAN Gynaecological Group. Clinical Management Protocols vulval cancer SE Scotland Cancer Network SCAN Gynaecological Group Clinical Management Protocols vulval cancer 2009 www.scan.scot.nhs.uk August 2001 updated annually, most recently INTRODUCTION The South East Scotland

More information

*OPERATIVE PROCEDURE. Serum tumour markers within normal limits S1.04 PRINCIPAL CLINICIAN

*OPERATIVE PROCEDURE. Serum tumour markers within normal limits S1.04 PRINCIPAL CLINICIAN Neoplasia of the Testis - Orchidectomy Histopathology Reporting Proforma Includes the International Collaboration on Cancer reporting dataset denoted by * Family name Given name(s) Date of birth Indigenous

More information

Vulvar Carcinoma. Definition: Cases should be classified as carsinoma of the vulva when the primary site growth is in the vulva Malignant melanoma sho

Vulvar Carcinoma. Definition: Cases should be classified as carsinoma of the vulva when the primary site growth is in the vulva Malignant melanoma sho Carcinoma Vulva & Vagina Subdivisi Onkologi Ginekologi Bagian Obgin FK USU Vulvar Carcinoma. Definition: Cases should be classified as carsinoma of the vulva when the primary site growth is in the vulva

More information

3/25/2019. J. Anthony Rakowski D.O., F.A.C.O.O.G. MSU SCS Board Review Coarse

3/25/2019. J. Anthony Rakowski D.O., F.A.C.O.O.G. MSU SCS Board Review Coarse J. Anthony Rakowski D.O., F.A.C.O.O.G. MSU SCS Board Review Coarse 1 4 th most common GYN cancer 5% of malignancies of GYN type. 4850 new cases annually 1030 deaths Cigarette smoking Vulvar dystrophy (Lichen

More information

Diseases of the vulva

Diseases of the vulva Diseases of the vulva 1. Bartholin Cyst - Infection of the Bartholin gland produces an acute inflammation within the gland (adenitis) and may result in an abscess. Bartholin duct cysts - Are relatively

More information

Clinical Pathological Conference. Malignant Melanoma of the Vulva

Clinical Pathological Conference. Malignant Melanoma of the Vulva Clinical Pathological Conference Malignant Melanoma of the Vulva History F/48 Chinese Married Para 1 Presented in September 2004 Vulval mass for 2 months Associated with watery and blood stained discharge

More information

Guideline for the Management of Vulval Cancer

Guideline for the Management of Vulval Cancer Version History Guideline for the Management of Vulval Cancer Version Date Brief Summary of Change Issued 2.0 20.02.08 Endorsed by the Governance Committee 2.1 19.11.10 Circulated at NSSG meeting 2.2 13.04.11

More information

Proposed All Wales Vulval Cancer Guidelines. Dr Amanda Tristram

Proposed All Wales Vulval Cancer Guidelines. Dr Amanda Tristram Proposed All Wales Vulval Cancer Guidelines Dr Amanda Tristram Previous FIGO staging FIGO Stage Features TNM Ia Lesion confined to vulva with

More information

Bone Marrow Specimen (Aspirate and Trephine Biopsy) Proforma

Bone Marrow Specimen (Aspirate and Trephine Biopsy) Proforma Bone Marrow Specimen (Aspirate and Trephine Biopsy) Proforma Mandatory questions (i.e. protocol standards) are in bold (e.g. S1.03). Family name Given name(s) Sex Male Female Intersex/indeterminate Date

More information

Type I. Type II. Excess estrogen Lynch Endometrioid adenocarcinoma PTEN. High grade More aggressive Serous, Clear Cell p53

Type I. Type II. Excess estrogen Lynch Endometrioid adenocarcinoma PTEN. High grade More aggressive Serous, Clear Cell p53 Type I Excess estrogen Lynch Endometrioid adenocarcinoma PTEN Type II High grade More aggressive Serous, Clear Cell p53 Stage I IA IB Stage II Stage III IIIA IIIB IIIC IIIC1 IIIC2 Stage IV IVA IVB nodes

More information

Cervical cancer presentation

Cervical cancer presentation Carcinoma of the cervix: Carcinoma of the cervix is the second commonest cancer among women worldwide, with only breast cancer occurring more commonly. Worldwide, cervical cancer accounts for about 500,000

More information

Sentinel nodes. Location: Location: S1.04 Principal clinician. G1.01 Record other relevant information. S2.01 Number of specimens submitted

Sentinel nodes. Location: Location: S1.04 Principal clinician. G1.01 Record other relevant information. S2.01 Number of specimens submitted Invasive Breast Cancer Histopathology Reporting Proforma Mandatory questions (i.e. protocol standards) are in bold (e.g. S1.01). S1.01 Identification Family name Given name(s) Date of birth DD MM YYYY

More information

Protocol for the Examination of Specimens From Patients With Primary Carcinoma of the Vulva

Protocol for the Examination of Specimens From Patients With Primary Carcinoma of the Vulva Protocol for the Examination of Specimens From Patients With Primary Carcinoma of the Vulva Version: Protocol Posting Date: June 2017 Includes ptnm requirements from the 8 th Edition, AJCC Staging Manual,

More information

ACCME/Disclosures. 52 year old man who consulted for a long-standing mass on the distal penis 4/13/2016

ACCME/Disclosures. 52 year old man who consulted for a long-standing mass on the distal penis 4/13/2016 ACCME/Disclosures United States and Canadian Academy of Pathology Seattle, WA 2016 Elsa F Velazquez, MD Director of Dermatopathology, V.P. Clinical Assistant Professor of Dermatology Tufts University,

More information

Done by khozama jehad. Neoplasia of the cervix

Done by khozama jehad. Neoplasia of the cervix Done by khozama jehad Neoplasia of the cervix An overview of cervical neoplasia very import. Most tumors of the cervix are of epithelial origin and are caused by oncogenic strains of human papillomavirus

More information

Review Article Selective Inguinal Lymphadenectomy in the Treatment of Invasive Squamous Cell Carcinoma of the Vulva

Review Article Selective Inguinal Lymphadenectomy in the Treatment of Invasive Squamous Cell Carcinoma of the Vulva Hindawi Publishing Corporation International Journal of Surgical Oncology Volume 2011, Article ID 284374, 6 pages doi:10.1155/2011/284374 Review Article Selective Inguinal Lymphadenectomy in the Treatment

More information

Staging and Treatment Update for Gynecologic Malignancies

Staging and Treatment Update for Gynecologic Malignancies Staging and Treatment Update for Gynecologic Malignancies Bunja Rungruang, MD Medical College of Georgia No disclosures 4 th most common new cases of cancer in women 5 th and 6 th leading cancer deaths

More information

Definition of Synoptic Reporting

Definition of Synoptic Reporting Definition of Synoptic Reporting The CAP has developed this list of specific features that define synoptic reporting formatting: 1. All required cancer data from an applicable cancer protocol that are

More information

Vaginal intraepithelial neoplasia

Vaginal intraepithelial neoplasia Vaginal intraepithelial neoplasia The terminology and pathology of VAIN are analogous to those of CIN (VAIN I-III). The main difference is that vaginal epithelium does not normally have crypts, so the

More information

The International Federation of Gynecology and Obstetrics (FIGO) updated the staging

The International Federation of Gynecology and Obstetrics (FIGO) updated the staging Continuing Education Column Revised FIGO Staging System Hee Sug Ryu, MD Department of Obstetrics and Gynecology, Ajou University School of Medicine E - mail : hsryu@ajou.ac.kr J Korean Med Assoc 2010;

More information

GUIDELINES ON PENILE CANCER

GUIDELINES ON PENILE CANCER GUIDELINES ON PENILE CANCER (Text updated March 2005) G. Pizzocaro (chairman), F. Algaba, S. Horenblas, H. van der Poel, E. Solsona, S. Tana, N. Watkin 58 Penile Cancer Eur Urol 2004;46(1);1-8 Introduction

More information

Squamous vulval cancer an update

Squamous vulval cancer an update DOI: 10.1111/tog.12059 The Obstetrician & Gynaecologist http://onlinetog.org 2013;15:227 31 Review Squamous vulval cancer an update Claire Bailey MRCOG, 1, * David Luesley MA MD FRCOG 2 1 Specialist Trainee,

More information

Catholic University of Louvain, St - Luc University Hospital Head and Neck Oncology Programme. Anatomopathology. Pathology 1 Sept.

Catholic University of Louvain, St - Luc University Hospital Head and Neck Oncology Programme. Anatomopathology. Pathology 1 Sept. Anatomopathology Pathology 1 Anatomopathology Biopsies Frozen section Surgical specimen Peculiarities for various tumor site References Pathology 2 Biopsies Minimum data, which should be given by the pathologist

More information

LOINC. Clinical information. RCPA code. Record if different to report header Operating surgeon name and contact details. Absent.

LOINC. Clinical information. RCPA code. Record if different to report header Operating surgeon name and contact details. Absent. Complete as narrative or use the structured format below 55752-0 17.02.28593 Clinical information 22027-7 17.02.30001 Record if different to report header Operating surgeon name and contact details 52101004

More information

Greater Manchester and Cheshire HPB Unit Guidelines for the Assessment & Management of Hepatobiliary and Pancreatic Disease Chapter 14

Greater Manchester and Cheshire HPB Unit Guidelines for the Assessment & Management of Hepatobiliary and Pancreatic Disease Chapter 14 Greater Manchester and Cheshire HPB Unit Guidelines for the Assessment & Management of Hepatobiliary and Pancreatic Disease Chapter 14 Contents 14. Neuroendocrine Tumours 161 14.1. Diagnostic algorithm

More information

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER CERVIX

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER CERVIX PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER CERVIX Site Group: Gynecology Cervix Author: Dr. Stephane Laframboise 1. INTRODUCTION 3 2. PREVENTION 3 3. SCREENING AND

More information

Kidney Case 1 SURGICAL PATHOLOGY REPORT

Kidney Case 1 SURGICAL PATHOLOGY REPORT Kidney Case 1 Surgical Pathology Report February 9, 2007 Clinical History: This 45 year old woman was found to have a left renal mass. CT urography with reconstruction revealed a 2 cm medial mass which

More information

Disorders of the vulva

Disorders of the vulva Vulval lesions Disorders of the vulva Terminology standardised by the International Society for the Study of Vulvovaginal Disease(ISSVD) Classification 1.Nonneoplastic epithelial disorders of vulva Lichen

More information

The Case of Mrs. Virginia Jones* Asst. Professor Division of Gyne-Oncology University of British Columbia, Department of Gynecology Vancouver, Canada

The Case of Mrs. Virginia Jones* Asst. Professor Division of Gyne-Oncology University of British Columbia, Department of Gynecology Vancouver, Canada Case title: Case authors: Case synopsis: The Case of Mrs. Virginia Jones* Dr. Leslie A. Sadownik Asst. Professor Division of Gyne-Oncology University of British Columbia, Department of Gynecology Vancouver,

More information

Uterine Cervix. Protocol applies to all invasive carcinomas of the cervix.

Uterine Cervix. Protocol applies to all invasive carcinomas of the cervix. Uterine Cervix Protocol applies to all invasive carcinomas of the cervix. Protocol revision date: January 2005 Based on AJCC/UICC TNM, 6 th edition and FIGO 2001 Annual Report Procedures Cytology (No Accompanying

More information

Session Number: 1020 Session: Adenocarcinoma of the Cervix: Diagnostic Pitfalls and New Prognostic Implications. Andres A. Roma, MD Cleveland Clinic

Session Number: 1020 Session: Adenocarcinoma of the Cervix: Diagnostic Pitfalls and New Prognostic Implications. Andres A. Roma, MD Cleveland Clinic Session Number: 1020 Session: Adenocarcinoma of the Cervix: Diagnostic Pitfalls and New Prognostic Implications Andres A. Roma, MD Cleveland Clinic No Disclosures In the past 12 months, I have not had

More information

Disclosures. I have no conflicts of interest to disclose. Vulvar Disease. Precancer and Cancerous Vulvar Disease

Disclosures. I have no conflicts of interest to disclose. Vulvar Disease. Precancer and Cancerous Vulvar Disease Precancer and Cancerous Vulvar Disease Stefanie M. Ueda, M.D. Disclosures I have no conflicts of interest to disclose. Assistant Clinical Professor Division of Gynecologic Oncology University of California,

More information

Case Scenario 1 Worksheet. Primary Site C44.4 Morphology 8743/3 Laterality 0 Stage/ Prognostic Factors

Case Scenario 1 Worksheet. Primary Site C44.4 Morphology 8743/3 Laterality 0 Stage/ Prognostic Factors CASE SCENARIO 1 9/10/13 HISTORY: Patient is a 67-year-old white male and presents with lesion located 4-5cm above his right ear. The lesion has been present for years. No lymphadenopathy. 9/10/13 anterior

More information

CPC on Cervical Pathology

CPC on Cervical Pathology CPC on Cervical Pathology Dr. W.K. Ng Senior Medical Officer Department of Clinical Pathology Pamela Youde Nethersole Eastern Hospital Cervical Smear: High Grade SIL (CIN III) Cervical Smear: High Grade

More information

Protocol for the Examination of Specimens from Patients with Carcinoma of the Vulva

Protocol for the Examination of Specimens from Patients with Carcinoma of the Vulva Protocol for the Examination of Specimens from Patients with Carcinoma of the Vulva Protocol applies to all invasive carcinomas of the vulva. Based on AJCC/UICC TNM, 7th edition, and FIGO 2008 Annual Report

More information

Japan Society of Gynecologic Oncology guidelines 2015 for the treatment of vulvar cancer and vaginal cancer

Japan Society of Gynecologic Oncology guidelines 2015 for the treatment of vulvar cancer and vaginal cancer Int J Clin Oncol (2018) 23:201 234 https://doi.org/10.1007/s10147-017-1193-z SPECIAL ARTICLE Japan Society of Gynecologic Oncology guidelines 2015 for the treatment of vulvar cancer and vaginal cancer

More information

Penile cancer teams in UK. Common variants. Penile cancer teams. Basaloid squamous carcinoma. The Pathology of Penile Tumours

Penile cancer teams in UK. Common variants. Penile cancer teams. Basaloid squamous carcinoma. The Pathology of Penile Tumours The Pathology of Penile Tumours Dr Jonathan H Shanks The Christie NHS Foundation Trust, Manchester, UK Penile cancer teams in UK 12 centres for penile cancer work (10 in England and Wales, 2 in Scotland)

More information

AJCC Cancer Staging 8 th edition. Lip and Oral Cavity Oropharynx (p16 -) and Hypopharynx Larynx

AJCC Cancer Staging 8 th edition. Lip and Oral Cavity Oropharynx (p16 -) and Hypopharynx Larynx AJCC Cancer Staging 8 th edition Lip and Oral Cavity Oropharynx (p16 -) and Hypopharynx Larynx AJCC 7 th edition Lip and Oral cavity Pharynx Larynx KEY CHANGES Skin of head and neck (Vermilion of the lip)

More information

8. The polyp in the illustration can be described as (circle all that apply) a. Exophytic b. Pedunculated c. Sessile d. Frank

8. The polyp in the illustration can be described as (circle all that apply) a. Exophytic b. Pedunculated c. Sessile d. Frank Quiz 1 Overview 1. Beginning with the cecum, which is the correct sequence of colon subsites? a. Cecum, ascending, splenic flexure, transverse, hepatic flexure, descending, sigmoid. b. Cecum, ascending,

More information

Small Intestine. Protocol revision date: January 2005 Based on AJCC/UICC TNM, 6 th edition

Small Intestine. Protocol revision date: January 2005 Based on AJCC/UICC TNM, 6 th edition Small Intestine Protocol applies to all invasive carcinomas of the small intestine, including those with focal endocrine differentiation. Excludes carcinoid tumors, lymphomas, and stromal tumors (sarcomas).

More information

Clinically Microscopically Pathogenesis: autoimmune not lifetime

Clinically Microscopically Pathogenesis: autoimmune not lifetime Vulvar Diseases: Can be divided to non-neoplastic and neoplastic diseases. The neoplastic diseases are much less common. Of those, squamous cell carcinoma is the most common. most common in postmenopausal

More information

Carcinoma of the Cervix Histopathology Reporting Guide

Carcinoma of the Cervix Histopathology Reporting Guide Carcinoma of the Cervix Histopathology Reporting Guide Family/Last name Given name(s) Date of birth DD MM YYYY Patient identifiers Date of request Accession/Laboratory number DD MM YYYY Elements in black

More information

GUIDELINES ON PENILE CANCER

GUIDELINES ON PENILE CANCER GUIDELINES ON PENILE CANCER (Text update April 2010) G. Pizzocaro, F. Algaba, S. Horenblas, E. Solsona, S. Tana, H. Van Der Poel, N. Watkin 78 Penile Cancer Eur Urol 2010 Jun;57(6):1002-12 Introduction

More information

Collaborative Staging Manual and Coding Instructions Part II: Primary Site Schema

Collaborative Staging Manual and Coding Instructions Part II: Primary Site Schema C44.0-C44.9, C51.0-C51.2, C51.8-C51.9, C60.0-C60.2, C60.8-C60.9, C63.2 (M-8720-8790) C44.0 Skin of lip, NOS C44.1 Eyelid C44.2 External ear C44.3 Skin of ear and unspecified parts of face C44.4 Skin of

More information

GUIDELINES ON PENILE CANCER

GUIDELINES ON PENILE CANCER 46 E. Solsona (chairman), F. Algaba, S. Horenblas, G. Pizzocaro, T. Windahl Eur Urol 2002;42(3):199-203 Introduction Penile carcinoma is an uncommon malignant disease with an incidence ranging from 0.1

More information

CLINICAL EFFECTIVENESS

CLINICAL EFFECTIVENESS Re-audit of gastrointestinal tract specimens with respect to compliance with RCPath guidelines Dr Manisha Ram Dr Moina Kadri Background epidemiology and aetiology Over the past 20 years there has been

More information

MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER

MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER 10 MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER Recommendations from the EAU Working Party on Muscle Invasive and Metastatic Bladder Cancer G. Jakse (chairman), F. Algaba, S. Fossa, A. Stenzl, C. Sternberg

More information

Case Report A Rare Cutaneous Adnexal Tumor: Malignant Proliferating Trichilemmal Tumor

Case Report A Rare Cutaneous Adnexal Tumor: Malignant Proliferating Trichilemmal Tumor Case Reports in Medicine Volume 2015, Article ID 742920, 4 pages http://dx.doi.org/10.1155/2015/742920 Case Report A Rare Cutaneous Adnexal Tumor: Malignant Proliferating Trichilemmal Tumor Omer Alici,

More information

Cervical Cancer 3/25/2019. Abnormal vaginal bleeding

Cervical Cancer 3/25/2019. Abnormal vaginal bleeding Cervical Cancer Abnormal vaginal bleeding Postcoital, intermenstrual or postmenopausal Vaginal discharge Pelvic pain or pressure Asymptomatic In most patients who are not sexually active due to symptoms

More information

SENTINEL NODES FOR EARLY VULVAL CANCER:

SENTINEL NODES FOR EARLY VULVAL CANCER: SENTINEL NODES FOR EARLY VULVAL CANCER: FEASIBILITY AND SAFETY IN A LOW RESOURCE SETTING LINDA ROGERS RCOG Congress 2017 None Declaration of Interests Vulval Cancer Rare 4% of all gynaecological malignancies

More information

ACRIN 6666 Therapeutic Surgery Form

ACRIN 6666 Therapeutic Surgery Form S1 ACRIN 6666 Therapeutic Surgery Form 6666 Instructions: Complete a separate S1 form for each separate area of each breast excised with the intent to treat a cancer (e.g. each lumpectomy or mastectomy).

More information

Urinary Bladder, Ureter, and Renal Pelvis

Urinary Bladder, Ureter, and Renal Pelvis Urinary Bladder, Ureter, and Renal Pelvis Protocol applies to all carcinomas of the urinary bladder, ureter, and renal pelvis. Protocol revision date: January 2005 Based on AJCC/UICC TNM, 6th edition Procedures

More information

1. Written information to patient /GP: fax ASAP to GP & offer copy of consultation letter.

1. Written information to patient /GP: fax ASAP to GP & offer copy of consultation letter. Skin Cancer follow up guidelines If NEW serious diagnosis given: 1. Written information to patient /GP: fax ASAP to GP & offer copy of consultation letter. 2. Free prescription information details. 3.

More information

6. Cervical Lymph Nodes and Unknown Primary Tumors of the Head and Neck

6. Cervical Lymph Nodes and Unknown Primary Tumors of the Head and Neck 1 Terms of Use The cancer staging form is a specific document in the patient record; it is not a substitute for documentation of history, physical examination, and staging evaluation, or for documenting

More information

Staging Classifications and Clinical Practice Guidelines for Gynaecological Cancers

Staging Classifications and Clinical Practice Guidelines for Gynaecological Cancers Pages 10/10/06 10:29 Page i Staging Classifications and Clinical Practice Guidelines for Gynaecological Cancers Emeritus Editor: JL Benedet Editors: Sergio Pecorelli, Hextan YS Ngan and Neville F Hacker

More information

Vulvar cancer: Know what to expect

Vulvar cancer: Know what to expect Vulvar cancer: Know what to expect For women with vulvar cancer What is the vulva? The vulva is the external (outside) part of the female genitals. The vulva includes the outer and inner lip, the clitoris,

More information

Correlation of intermediate risk factors with prognostic factors in patients with early cervical cancer

Correlation of intermediate risk factors with prognostic factors in patients with early cervical cancer 대한부인종양콜포스코피학회제 24 차학술대회 Correlation of intermediate risk factors with prognostic factors in patients with early cervical cancer Seoul National University Bundang Hospital Eun Jung Soh, M.D. Cervical cancer

More information

Cervical Cancer: 2018 FIGO Staging

Cervical Cancer: 2018 FIGO Staging Cervical Cancer: 2018 FIGO Staging Jonathan S. Berek, MD, MMS Laurie Kraus Lacob Professor Stanford University School of Medicine Director, Stanford Women s Cancer Center Senior Scientific Advisor, Stanford

More information

L ARYNX S TAGING F ORM

L ARYNX S TAGING F ORM CLI N I CA L Extent of disease before any treatment y clinical staging completed after neoadjuvant therapy but before subsequent surgery TX T0 Tis a b L ARYNX S TAGING F ORM LATERALITY: TUMOR SIZE: left

More information

EAU GUIDELINES ON PENILE CANCER

EAU GUIDELINES ON PENILE CANCER EAU GUIDELINES ON PENILE CANCER (Text update April 2014) O.W. Hakenberg (Chair), N. Watkin, E. Compérat, S. Minhas, A. Necchi, C. Protzel Introduction and epidemiology The incidence of penile cancer increases

More information

Head & Neck Squamous Carcinoma: Artifacts, Challenges, and Controversies. Agenda

Head & Neck Squamous Carcinoma: Artifacts, Challenges, and Controversies. Agenda Head & Neck Squamous Carcinoma: Artifacts, Challenges, and Controversies Jennifer L. Hunt, MD, MEd Aubrey J. Hough Jr, MD, Endowed Professor of Pathology Chair of Pathology and Laboratory Medicine University

More information

Melanoma Quality Reporting

Melanoma Quality Reporting Melanoma Quality Reporting September 1, 2013 December 31, 2016 Laurence McCahill, MD Surgical Oncologist Metro Health Surgical Oncology Metro Health Professional Building 2122 Health Drive SW Wyoming,

More information

Colon and Rectum. Protocol revision date: January 2005 Based on AJCC/UICC TNM, 6th edition

Colon and Rectum. Protocol revision date: January 2005 Based on AJCC/UICC TNM, 6th edition Colon and Rectum Protocol applies to all invasive carcinomas of the colon and rectum. Carcinoid tumors, lymphomas, sarcomas, and tumors of the vermiform appendix are excluded. Protocol revision date: January

More information

This form may provide more data elements than required for collection by standard setters such as NCI SEER, CDC NPCR, and CoC NCDB.

This form may provide more data elements than required for collection by standard setters such as NCI SEER, CDC NPCR, and CoC NCDB. 1 Terms of Use The cancer staging form is a specific document in the patient record; it is not a substitute for documentation of history, physical examination, and staging evaluation, or for documenting

More information

Enrollment Form: Pancreas

Enrollment Form: Pancreas Tissue Source Site (TSS) Name: TSS Identifier: _ TSS Unique Patient #: Completed By: Completion Date (MM/DD/YYYY): Form Notes: An Enrollment Form should be completed for each TCGA qualified case upon qualification

More information

VIN/VAIN O C T O B E R 3 RD J M O R G A N

VIN/VAIN O C T O B E R 3 RD J M O R G A N VIN/VAIN O C T O B E R 3 RD 2 0 1 8 J M O R G A N Vaginal Intraepithelial Neoplasia VAIN I, II, III Incidence 0.1/100,000 women in US Mean age 50s (J Womens Health (Larchmt) 2009:18:1731) (J Obstet Gynaecol

More information

Handling & Grossing of Colo-rectal Specimens for Tumours. for Medical Officers in Pathology

Handling & Grossing of Colo-rectal Specimens for Tumours. for Medical Officers in Pathology Handling & Grossing of Colo-rectal Specimens for Tumours for Medical Officers in Pathology Dr Gayana Mahendra Department of Pathology Faculty of Medicine University of Kelaniya Your Role in handling colorectal

More information

Technicians & Nurses Program

Technicians & Nurses Program ASCRS ASOA Symposium & Congress Technicians & Nurses Program May 6-10, 2016 New Orleans Evaluation and Treatment of Eyelid Malignancies Richard C. Allen MD PhD FACS Professor Section of Ophthalmology Dept.

More information

A215- Urinary bladder cancer tissues

A215- Urinary bladder cancer tissues A215- Urinary bladder cancer tissues (formalin fixed) For research use only Specifications: No. of cases: 45 Tissue type: Urinary bladder cancer tissues No. of spots: 2 spots from each cancer case (90

More information

Objectives. Atypical Glandular Cells. Atypical Endocervical Cells. Reactive Endocervical Cells

Objectives. Atypical Glandular Cells. Atypical Endocervical Cells. Reactive Endocervical Cells 2013 California Society of Pathologists 66 th Annual Meeting San Francisco, CA Atypical Glandular Cells to Early Invasive Adenocarcinoma: Cervical Cytology and Histology Christina S. Kong, MD Associate

More information

Da Costa was the first to coin the term. Marjolin s Ulcer: A Case Report and Literature Review. Case Report. Introduction

Da Costa was the first to coin the term. Marjolin s Ulcer: A Case Report and Literature Review. Case Report. Introduction E-Da Medical Journal 2016;3(2):24-28 Case Report Marjolin s Ulcer: A Case Report and Literature Review Yue-Chiu Su 1, Li-Ren Chang 2 Marjolin s ulcer is an aggressive cutaneous malignancy, which is common

More information

UICC TNM 8 th Edition Errata

UICC TNM 8 th Edition Errata UICC TNM 8 th Edition Errata ions are in italics Page 28 Oropharynx p16 positive Pathological Stage II,T2 N2 M0 T3 N0,N1 M0 Stage II,T2 N2 M0 T3,T4 N0,N1 M0 Page 61 Oesophagus Adenocarcinoma Pathological

More information

VULVAR CANCER GUIDELINES

VULVAR CANCER GUIDELINES VULVAR ANER GUIDELINES www.esgo.org Broz_210x297_9_16_b.indd 1 13.09.16 21:48 The European Society of Gynaecological Oncology (ESGO) developed guidelines covering diagnosis and referral, preoperative investigations,

More information

Prognostic factors associated with local recurrence in squamous cell carcinoma of the vulva

Prognostic factors associated with local recurrence in squamous cell carcinoma of the vulva Original Article J Gynecol Oncol Vol. 24, No. 3:242-248 pissn 2005-0380 eissn 2005-0399 Prognostic factors associated with local recurrence in squamous cell carcinoma of the vulva Sara Iacoponi, Ignacio

More information

Protocol applies to melanoma of cutaneous surfaces only.

Protocol applies to melanoma of cutaneous surfaces only. Melanoma of the Skin Protocol applies to melanoma of cutaneous surfaces only. Procedures Biopsy (No Accompanying Checklist) Excision Re-excision Protocol revision date: January 2005 Based on AJCC/UICC

More information

Pancreas (Exocrine) Protocol applies to all carcinomas of the exocrine pancreas.

Pancreas (Exocrine) Protocol applies to all carcinomas of the exocrine pancreas. Pancreas (Exocrine) Protocol applies to all carcinomas of the exocrine pancreas. Protocol revision date: January 2005 Based on AJCC/UICC TNM, 6 th edition Procedures Cytology (No Accompanying Checklist)

More information

EAU GUIDELINES ON PENILE CANCER

EAU GUIDELINES ON PENILE CANCER EAU GUIDELINES ON PENILE CANCER (Text update April 2014) O.W. Hakenberg (Chair), E. Compérat, S. Minhas, A. Necchi, C. Protzel, N. Watkin Guidelines Associate: R. Robinson Introduction and epidemiology

More information

C ORPUS UTERI C ARCINOMA STAGING FORM (Carcinosarcomas should be staged as carcinomas)

C ORPUS UTERI C ARCINOMA STAGING FORM (Carcinosarcomas should be staged as carcinomas) C ORPUS UTERI C ARCINOMA STAGING FORM CLINICAL Extent of disease before any treatment y clinical staging completed after neoadjuvant therapy but before subsequent surgery Tis * T1 I T1a IA NX N0 N1 N2

More information

You Are Going to Cut How Much Skin? Locoregional Surgical Treatment. Justin Rivard MD, MSc, FRCSC September 21, 2018

You Are Going to Cut How Much Skin? Locoregional Surgical Treatment. Justin Rivard MD, MSc, FRCSC September 21, 2018 You Are Going to Cut How Much Skin? Locoregional Surgical Treatment Justin Rivard MD, MSc, FRCSC September 21, 2018 Presenter Disclosure Faculty/Speaker: Justin Rivard Relationships with financial sponsors:

More information

2018 New Required Data Items for Hospitals

2018 New Required Data Items for Hospitals 2018 New Required Data Items for Hospitals The NJSCR is a population-based registry, mandated by state law, that collects data on all cancer cases diagnosed and/or treated in New Jersey since October 1,

More information

NUMERATOR: Reports that include the pt category, the pn category and the histologic grade

NUMERATOR: Reports that include the pt category, the pn category and the histologic grade Quality ID #100 (NQF 0392): Colorectal Cancer Resection Pathology Reporting: pt Category (Primary Tumor) and pn Category (Regional Lymph Nodes) with Histologic Grade National Quality Strategy Domain: Effective

More information

Melanoma Case Scenario 1

Melanoma Case Scenario 1 Melanoma Case Scenario 1 History and physical 11/5/16 Patient is a single, 48-year-old male in good health who presented to his primary physician for a yearly physical exam during which a 3.4 x 2.8 x 1.5

More information

Surgical Margins in Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma

Surgical Margins in Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma Surgical Margins in Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma Consensus update and recommendations, 2018 Head and Neck Steering Committee P. Gorphe *, F. Nguyen, Y. Tao, P. Blanchard,

More information

GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER

GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER (Limited text update December 21) M. Babjuk, W. Oosterlinck, R. Sylvester, E. Kaasinen, A. Böhle, J. Palou, M. Rouprêt Eur Urol 211 Apr;59(4):584-94 Introduction

More information

NUMERATOR: Reports that include the pt category, the pn category and the histologic grade

NUMERATOR: Reports that include the pt category, the pn category and the histologic grade Quality ID #100 (NQF 0392): Colorectal Cancer Resection Pathology Reporting: pt Category (Primary Tumor) and pn Category (Regional Lymph Nodes) with Histologic Grade National Quality Strategy Domain: Effective

More information

MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER

MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER (Text update March 2008) A. Stenzl (chairman), N.C. Cowan, M. De Santis, G. Jakse, M. Kuczyk, A.S. Merseburger, M.J. Ribal, A. Sherif, J.A. Witjes Introduction

More information